Literature DB >> 19995815

Why don't we have all the evidence on oseltamivir?

Fiona Godlee, Mike Clarke.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19995815     DOI： 10.1136/bmj.b5351

Source DB:  PubMed          Journal:  BMJ        ISSN： 0959-8138


× No keyword cloud information.
  6 in total

Review 1.  Oseltamivir in seasonal, avian H5N1 and pandemic 2009 A/H1N1 influenza: pharmacokinetic and pharmacodynamic characteristics.

Authors:  Nicolas Widmer; Pascal Meylan; Anton Ivanyuk; Manel Aouri; Laurent A Decosterd; Thierry Buclin
Journal:  Clin Pharmacokinet       Date:  2010-11       Impact factor: 6.447

2.  [Influenza : clinical symptoms, diagnostics and therapy].

Authors:  G G U Rohde
Journal:  Internist (Berl)       Date:  2011-09       Impact factor: 0.743

3.  Oseltamivir and risk of lower respiratory tract complications in patients with flu symptoms: a meta-analysis of eleven randomized clinical trials.

Authors:  Miguel A Hernán; Marc Lipsitch
Journal:  Clin Infect Dis       Date:  2011-06-15       Impact factor: 9.079

Review 4.  Reporting bias in medical research - a narrative review.

Authors:  Natalie McGauran; Beate Wieseler; Julia Kreis; Yvonne-Beatrice Schüler; Heike Kölsch; Thomas Kaiser
Journal:  Trials       Date:  2010-04-13       Impact factor: 2.279

5.  Promoting transparency in pharmaceutical industry-sponsored research.

Authors:  Joseph S Ross; Cary P Gross; Harlan M Krumholz
Journal:  Am J Public Health       Date:  2011-11-28       Impact factor: 9.308

Review 6.  Neuraminidase inhibitors for preventing and treating influenza in adults and children.

Authors:  Tom Jefferson; Mark A Jones; Peter Doshi; Chris B Del Mar; Rokuro Hama; Matthew J Thompson; Elizabeth A Spencer; Igho Onakpoya; Kamal R Mahtani; David Nunan; Jeremy Howick; Carl J Heneghan
Journal:  Cochrane Database Syst Rev       Date:  2014-04-10
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.